US EditionEc Approves a Triple Dose of Current Wegovy, Which Achieves Weight Loss of 21%
4 Articles
4 Articles
The European Commission has approved a new maintenance dose of Wegovy (semagglutide injection) of 7.2 mg — three times the maximum previously authorised, 2.4 mg. The announcement was made by the Danish New Nordisk pharmacothecist, who produced the medicine indicated for the treatment of obesity. More Eric Dane: understands the amytrophic lateral sclerosis (ELA), a disease against which the star 'Grey's Anatomy' has been fighting since 2025 Super…
Novo Nordisk has reported that the European Commission has approved the inclusion in the SPC of Wegovy (semaglutide) data from the Step Up clinical program, which shows that a dose of 7.2 mg, three times higher than the current one (2.4 mg), achieves a weight loss of up to 21% in people with obesity.Continue reading...
Danish pharmaceutical company Novo Nordisk received approval for a high-dose 7.2mg Wigobi (active ingredient semaglutide) for the obesity treatment from the European Commission on the 17th (local time). Following approval in the UK, the European Commission is also...
The medicinal product, subject to medical prescription, to reduce appetite and increase sensitisation, will now have versions with doses of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg. Oral format, in tablets, is only available in the USA
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
